Related Experiment Videos
Randomized clinical trials--am I by brother's keeper?
Abstract:
If reasonable effective therapy for a disease is available, is it then ethical to conduct placebo-controlled studies with other unproven, but potentially beneficial, agents? Some investigators prefer to use proven-therapy controls when evaluating new drugs; however, random tests done with a placebo provide more accurate results. Therefore, when may society expose some human beings to potential harm in order to seek future benefits for society as a whole? A study done by Peterson and Elashoff suggested that a placebo-controlled trials is "clearly unethical" because the patient-subjects are a "high risk," and that "informed consent" becomes a fiction because no patient who clearly understood the implications of these trials would consent. Subjects; preferences have not been given much weight. Chalmers and associates maintain that randomization studies, which have also neglected patients' preferences, are more ethical than testing new therapies in an unscientific manner. Chalmers and others stressed that the physician must believe that he has "no knowledge at all that one treatment will be better or worse, safer or more dangerous than another." Some feel that active participation by patients would expose them to greater-than-warranted risks. The FDA has stated that informed consent should be obtained from each subject or representative before he or she may participate in clinical investigation. We suggest that only the patient and investigator make the decision to participate in a joint undertaking, not the profession or the state. This will require an open dialogue between physicians and patients, with each group taking responsibility for themselves and for each other.
Insights
Conducting placebo-controlled trials for new drugs is ethically complex when effective treatments exist. Patient-physician dialogue is crucial for informed consent and shared decision-making in clinical research.
Area of Science:
- Medical Ethics
- Clinical Trial Design
- Patient Autonomy
Background:
- The ethical implications of placebo-controlled trials are debated when effective therapies are available.
- Balancing the pursuit of scientific accuracy with patient welfare is a key ethical challenge.
Purpose of the Study:
- To explore the ethical considerations of using placebo controls in clinical trials.
- To examine the role of informed consent and patient preferences in research ethics.
Main Methods:
- Review of ethical arguments regarding placebo vs. active-controlled trials.
- Analysis of informed consent challenges in high-risk patient populations.
- Discussion of regulatory perspectives (e.g., FDA) and professional opinions.
Main Results:
- Placebo-controlled trials may be considered unethical if effective treatments exist, particularly for high-risk patients.
- Informed consent can be compromised if patients fully understand the risks and alternatives.
- Patient preferences and autonomy should be prioritized in research decisions.
Conclusions:
- Ethical clinical investigations require a shift towards shared decision-making between patients and investigators.
- Open dialogue and mutual responsibility are essential for navigating the ethics of human subject research.
- The decision to participate in clinical trials should ultimately rest with the patient and investigator, not external bodies.